Methods of treating psychiatric disorders in obese patients with brexpiprazole
AssigneeLake O'Hara LLC
InventorsSundar Srinivasan, Christina Chow
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of initiating brexpiprazole treating in patients with schizophrenia or major depressive disorder. The present disclosure further relates to modified dosing regimens for obese patients and/or patients that are CYP2D6 poor metabolizers. In embodiments, the modified dosing regimens administers double the daily dose while initiating treatment.
Claims29
A method of initiating treatment of schizophrenia with brexpiprazole in an obese patient who is not a CYP2D6 poor metabolizer, comprising:
- (a) administering 1 mg brexpiprazole twice daily on each of the first 4 days of brexpiprazole treatment;
- (b) administering 2 mg brexpiprazole twice daily on each of the next 3 days following step (a);
- and then
- (c) administering a recommended dose of 2-4 mg/day brexpiprazole once daily thereafter;
- wherein the obese patient has a BMI of at least about 35.
A method of initiating treatment of schizophrenia with brexpiprazole in an obese patient who is a CYP2D6 poor metabolizer, comprising:
- (a) administering 0.5 mg brexpiprazole twice daily on each of the first 4 days of brexpiprazole treatment;
- (b) administering 1 mg brexpiprazole twice daily on each of the next 3 days following step (a);
- (c) administering 1-2 mg brexpiprazole twice daily on each of the next 7 days;
- and then
- (d) administering 1-2 mg/day of brexpiprazole once daily thereafter;
- wherein the obese patient has a BMI of at least about 35.
A method of initiating adjunctive treatment of major depressive disorder with brexpiprazole in an obese patient who is not a CYP2D6 poor metabolizer, comprising:
- (a) administering either 0.5 or 1 mg brexpiprazole twice daily on each of the first 7 days of brexpiprazole treatment;
- (b) administering double the individual brexpiprazole dose of step (a) once daily on each of the next 7 days following step (a);
- and then
- (c) administering the recommended daily dose of brexpiprazole once daily thereafter;
- wherein the obese patient has a BMI of at least about 35.
A method of initiating adjunctive treatment of major depressive disorder with brexpiprazole in an obese patient who is a CYP2D6 poor metabolizer, comprising:
- (a) administering 0.5 mg brexpiprazole twice daily on each of the first 7 days of brexpiprazole treatment;
- (b) administering 1 mg twice daily on each of the next 7 days following step (a);
- and then
- (c) administering 1-1.5 mg/day of brexpiprazole once daily thereafter;
- wherein the obese patient has a BMI of at least about 35.
Dependencies are inferred from the claim text.